Literature DB >> 14741443

Cannabinoid-mediated exacerbation of brain infection by opportunistic amebae.

Guy A Cabral1, Francine Marciano-Cabral.   

Abstract

Recent reports indicate a higher frequency of brain infections with opportunistic amebae of the genus Acanthamoeba among immune compromised individuals, including AIDS patients. We have demonstrated, using a murine model of Granulomatous Amebic Encephalitis (GAE), that the major psychoactive and immune suppressive component in marijuana delta-9-tetrahydrocannabinol (THC) exacerbates infection by these amebae. Mice administered THC and infected with Acanthamoeba exhibited dose-related higher mortalities than infected vehicle controls. The greater severity of disease for THC-treated mice was accompanied by decreased accumulation of macrophage-like cells at focal sites of infection in the brain. Furthermore, THC administration resulted in decreased levels of mRNA for the pro-inflammatory cytokines interleukin-1 alpha, interleukin-1 beta, and tumor necrosis factor alpha for neonatal rat microglia co-cultured with Acanthamoeba. These results indicate a potential for marijuana to alter the capacity of brain macrophage-like cells to mount a full complement of immune responsiveness to brain infection by opportunistic amebae.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14741443     DOI: 10.1016/j.jneuroim.2003.10.027

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  16 in total

Review 1.  Effects of Cannabinoids on T-cell Function and Resistance to Infection.

Authors:  Toby K Eisenstein; Joseph J Meissler
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-16       Impact factor: 4.147

Review 2.  Drugs of abuse, immune modulation, and AIDS.

Authors:  Guy A Cabral
Journal:  J Neuroimmune Pharmacol       Date:  2006-06-28       Impact factor: 4.147

Review 3.  Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.

Authors:  Guy A Cabral; LaToya Griffin-Thomas
Journal:  Expert Rev Mol Med       Date:  2009-01-20       Impact factor: 5.600

4.  Endocannabinoids inhibit the growth of free-living amoebae.

Authors:  Rafik Dey; Pierre Pernin; Jacques Bodennec
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

Review 5.  Cannabinoids as therapeutic agents for ablating neuroinflammatory disease.

Authors:  G A Cabral; L Griffin-Thomas
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-09       Impact factor: 2.895

6.  Chronic Δ⁹-tetrahydrocannabinol administration may not attenuate simian immunodeficiency virus disease progression in female rhesus macaques.

Authors:  Angela M Amedee; Whitney A Nichols; Nicole J LeCapitaine; Curtis Vande Stouwe; Leslie L Birke; Nedra Lacour; Peter J Winsauer; Patricia E Molina
Journal:  AIDS Res Hum Retroviruses       Date:  2014-12       Impact factor: 2.205

7.  Acanthamoeba culbertsoni elicits soluble factors that exert anti-microglial cell activity.

Authors:  Jenica L Harrison; Gabriela A Ferreira; Erinn S Raborn; Audrey D Lafrenaye; Francine Marciano-Cabral; Guy A Cabral
Journal:  Infect Immun       Date:  2010-07-06       Impact factor: 3.441

8.  Maternal marijuana use, adverse pregnancy outcomes, and neonatal morbidity.

Authors:  Torri D Metz; Amanda A Allshouse; Carol J Hogue; Robert L Goldenberg; Donald J Dudley; Michael W Varner; Deborah L Conway; George R Saade; Robert M Silver
Journal:  Am J Obstet Gynecol       Date:  2017-05-31       Impact factor: 8.661

9.  2-Arachidonoyl-glycerol- and arachidonic acid-stimulated neutrophils release antimicrobial effectors against E. coli, S. aureus, HSV-1, and RSV.

Authors:  François Chouinard; Caroline Turcotte; Xiaochun Guan; Marie-Chantal Larose; Samuel Poirier; Line Bouchard; Véronique Provost; Louis Flamand; Nathalie Grandvaux; Nicolas Flamand
Journal:  J Leukoc Biol       Date:  2012-12-12       Impact factor: 4.962

Review 10.  CB2 receptors in the brain: role in central immune function.

Authors:  G A Cabral; E S Raborn; L Griffin; J Dennis; F Marciano-Cabral
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.